Hair loss has become one of the more unsettling concerns surrounding GLP-1 drugs. The signal is no longer based only on social-media anecdotes: clinical trials, drug labels, pharmacovigilance reports, and a large 2026 observational study have all documented alopecia in some people using these medications, but that does not mean semaglutide, tirzepatide, or other GLP-1 receptor agonists have been proven to directly damage hair follicles. The best evidence so far points to a real association, while leaving a major question unresolved: is the drug itself responsible, or is hair shedding often a downstream effect of rapid weight loss and the metabolic changes that accompany it?
The strongest new evidence comes from real-world medical records
In July 2026, researchers published a target trial emulation in The BMJ using electronic health records from Penn Medicine. The study included adults with type 2 diabetes who newly started a GLP-1 receptor agonist, an SGLT-2 inhibitor, or a DPP-4 inhibitor between January 2019 and September 2024.
The comparison was designed to answer a more useful question than simply asking whether people taking GLP-1 drugs ever lose hair. The researchers compared GLP-1 users with patients starting other glucose-lowering medications and statistically balanced a range of baseline characteristics.
Among 12,004 GLP-1 initiators and 15,221 SGLT-2 inhibitor initiators, GLP-1 use was associated with a 37% higher relative hazard of alopecia. In a separate comparison involving 11,964 GLP-1 initiators and 11,238 DPP-4 inhibitor initiators, the relative hazard was 68% higher.
Those percentages sound large, but the absolute numbers provide essential context. Adjusted incidence rates were about 6.91 versus 5.04 cases per 1,000 person-years for GLP-1 drugs versus SGLT-2 inhibitors, and 6.53 versus 3.89 per 1,000 person-years versus DPP-4 inhibitors.
In other words, the study detected an association, but clinically diagnosed alopecia remained uncommon in all groups.
The signal was concentrated in non-scarring hair loss
When the researchers examined subtypes, the association was specific to non-scarring alopecia. GLP-1 users had a hazard ratio of 1.53 compared with SGLT-2 inhibitor users and 1.72 compared with DPP-4 inhibitor users.
That distinction matters. Scarring alopecias involve destruction of the hair follicle and can produce permanent loss. Non-scarring forms leave the follicle intact and include several conditions with very different causes and prognoses.
One biologically plausible explanation in people losing substantial weight is telogen effluvium, a diffuse shedding condition in which a physiologic stressor shifts an unusually large number of hair follicles from the growing phase into the resting phase. Noticeable shedding typically appears after a delay rather than immediately after the trigger.
Why rapid weight loss could matter
Rapid or substantial weight loss has long been recognized as a potential trigger for telogen effluvium. Reduced energy intake, changes in protein or micronutrient intake, illness, surgery, and other metabolic stresses can also disrupt the normal hair-growth cycle.
This creates a difficult causal problem for GLP-1 research. The medications are prescribed precisely because they can produce substantial weight loss. If hair shedding follows that weight change, an observational study may detect more alopecia among GLP-1 users even if the drug is not directly toxic to the follicle.
The BMJ investigators adjusted for baseline factors, including obesity, but they did not have the longitudinal weight trajectories needed to determine how much of the association was mediated by weight loss after treatment began. The authors therefore could not establish whether the medications themselves, weight loss, nutritional changes, or a combination of factors caused the observed difference.
This is similar to an issue we discussed in our GLP-1 drugs and muscle loss article: a change that occurs during pharmacologic weight loss is not automatically evidence of a unique toxic effect of the medication.
Hair loss already appears in the prescribing information
The observational findings are not the first signal. Hair loss is included in current US prescribing information for both Wegovy and Zepbound.
For Wegovy, the prescribing information states that hair-loss adverse reactions were associated with weight reduction. In pooled adult weight-management trials of the 2.4 mg injection, hair loss was reported in 3.3% of Wegovy-treated participants compared with 1% receiving placebo. The label also reports higher percentages in women than men.
Zepbound’s prescribing information similarly states that hair-loss adverse reactions were associated with weight reduction. In pooled weight-reduction trials, hair loss was reported in 5%, 4%, and 5% of participants receiving 5 mg, 10 mg, and 15 mg tirzepatide, respectively, compared with 1% receiving placebo.
These trial data are important because they show that hair loss was observed under controlled study conditions. But they still do not prove a direct follicular effect. Participants receiving active treatment also lost substantially more weight than participants receiving placebo.
Why the percentages from different studies should not be compared directly
The drug-label percentages are noticeably higher than the incidence rates in the BMJ medical-record study, but they measure different things.
Clinical trials actively collect adverse events from participants. Electronic health-record studies depend on a condition being recognized and coded during routine medical care. Mild shedding may never lead to a formal alopecia diagnosis, so a medical-record study can miss events that would be captured in a trial.
The populations also differ. The BMJ analysis specifically studied adults with type 2 diabetes, while obesity trials enroll people according to different criteria. The results therefore should not be treated as interchangeable estimates of an individual’s probability of losing hair.
Semaglutide and tirzepatide may not carry identical signals
The BMJ study included multiple GLP-1 receptor agonists and explored individual drugs in secondary analyses. Some estimates suggested stronger associations for semaglutide and tirzepatide, but drug-specific analyses involved fewer events and wider confidence intervals.
A 2025 systematic review also found that the literature was limited and inconsistent. It identified only five eligible primary studies and concluded that more research was needed to clarify the relationship between GLP-1 therapies and alopecia.
That is an important reason not to turn an emerging safety signal into a class-wide claim that every GLP-1 drug has the same effect. Tirzepatide also activates the GIP receptor, unlike selective GLP-1 receptor agonists such as semaglutide. Our tirzepatide mechanism explainer covers that pharmacologic distinction.
What should someone do if shedding starts?
Hair shedding has many possible causes, including thyroid disease, iron deficiency, recent illness, hormonal changes, medications, autoimmune disease, and genetic hair loss. Someone taking a GLP-1 drug can therefore develop alopecia for reasons unrelated to the medication.
A clinician can assess the pattern and timing of hair loss, the rate of weight change, dietary intake, other medications, and whether laboratory evaluation is appropriate. Sudden patchy loss, scalp inflammation, pain, scaling, or signs of scarring deserve particular attention because they are not the classic pattern expected from telogen effluvium.
Stopping a prescribed GLP-1 medication solely because of hair shedding is not automatically the right response. The metabolic and cardiovascular benefits can be substantial for appropriately selected patients, and the cause of the shedding may be treatable without discontinuing therapy. Medication changes should be discussed with the prescribing clinician.
For a broader look at adverse effects and warning signs, see our GLP-1 side-effects guide.
What the evidence actually supports
There is now credible evidence that hair loss occurs more often in some people treated with GLP-1-based weight-loss medications. Randomized weight-management trials detected the event, current prescribing information acknowledges it, and the 2026 BMJ analysis found a higher rate of diagnosed non-scarring alopecia compared with two other diabetes-drug classes.
What remains uncertain is the mechanism. The available evidence does not establish that GLP-1 receptor activation directly injures hair follicles. Rapid weight loss and associated nutritional or metabolic stress offer a plausible alternative explanation, and current observational data cannot fully separate those pathways.
So the most accurate conclusion is narrower than many headlines imply: GLP-1 treatment is associated with an increased risk of hair loss, but the absolute risk of clinically diagnosed alopecia appears low, and researchers still do not know how much of the signal comes from the drug itself versus the weight loss it produces.
References
- Tang H, Zhang B, Lu Y, et al. Risk of hair loss associated with glucagon-like peptide-1 receptor agonists in adults with type 2 diabetes: target trial emulation. BMJ. 2026;394:e100077. DOI: 10.1136/bmj-2026-100077.
- Novo Nordisk. Wegovy (semaglutide) prescribing information. 2026. Prescribing information.
- Eli Lilly and Company. Zepbound (tirzepatide) prescribing information. 2026. Prescribing information.
- Alsuwailem OA, Alanazi R, Almutairi HM, et al. Hair Loss Associated With Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Use: A Systematic Review. Cureus. 2025;17(9):e92454. DOI: 10.7759/cureus.92454.